Uso del factor VII activado recombinante como agente hemostático en trastornos hemorrágicos

effectiveness of the treatment with recombinant activated factor vii (ravii) during the hemorrhagic episodes in hemophilic patients using inhibitions and the knowledge of its action mechanism determined that in pas years its use will be expanded in patients with hemorrhage from non-controlled diverse causes using the usual therapeutics among other, congenital coagulation defects, platelet disorders, liver diseases, surgery, intracranial hemorrhage, digestive bleedings. although a significant group of these communications have been carried out in reported cases and in cases series, it is considered that the results obtained are important and that the administration of ravii is an alternative in patients presenting with non-controlled severe hemorrhage. despite its potent pro-coagulant action, thromboembolism complications risk is low and it is related to a significant group of patients with other prothrombotic factors. nowadays, it is considered that ravii is prescribed in those patients with massive hemorrhage without response either to therapy using blood components or appropriate surgical measures.